Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
Pierre Sié Hematology Laboratory, Academic Hospital of Toulouse, Hospital Rangueil, Toulouse, France Abstract: Idarucizumab is the first targeted antidote of dabigatran, a direct oral anticoagulant used for prevention and treatment of venous thromboembolism and prevention of stroke in atrial fibrill...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2016-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!